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Summary
We report the clinical features of 12 families with autosomal
dominant spastic paraplegia (ADSP) linked to the SPG4
locus on chromosome 2p, the major locus for this disorder
that accounts for ~40% of the families. Among 93 gene
carriers, 32 (34%) were unaware of symptoms but were
clinically affected. Haplotype reconstruction showed that
90% of the asymptomatic gene carriers presented increased
reflexes and/or extensor plantar responses independent of
age at examination. The mean age at onset was 29 years,
ranging from 1 to 63 years. Intra- as well as inter-familial
variability of age at onset was important, but did not result
from anticipation. Phenotype-genotype correlations and
comparison with SPG3 and SPG5 families indicated that
despite the variability of age at onset, SPG4 is a single
genetic entity but no clinical features distinguish individual
SPG4 patients from those with SPG3 or SPG5 mutations.
Keywords: spastic paraplegia; SPG4; linkage analysis; anticipation; genetic heterogeneity
Abbreviation: ADSP= autosomal dominant spastic paraplegia
Introduction
Spastic paraplegia, a hereditary disease first described by
Striimpell (1880) in two brothers, is characterized patho-
logically by degeneration of the corticospinal tracts and
thinning of the columns of Goll and spinocerebellar tracts.
A 'pure' form of the disease has been distinguished, but
its pattern of inheritance is variable. In patients with ADSP
in addition to pyramidal signs in the lower limbs, sphincter
disturbances and diminished vibration sense are frequently
observed (Polo et al., 1993; Durr et ai, 1994). Even
in the 'pure' form, paraclinical investigations revealed
asymptomatic multisystem involvement of the nervous
system (Tedeschi et al., 1991; Durr et ai, 1994). Age at
onset is highly variable, and Harding (1981) used this
parameter in a series of 61 patients to distinguish two
types of ADSP. In type I onset ranges from 20 to 40
years, in type II from 40 to 65 years. Sensory loss and
urinary symptoms were more frequent in the latter. Both
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types may be observed in a single family (Polo et al.,
1993; DUrr et al., 1994).
'Pure' ADSPs are genetically heterogeneous. There are
at least three loci, designated SPG3-5. The first was
assigned to chromosome 14q (SPG3) in a single French
family (Hazan et al., 1993). A German and a Tunisian
family were found to be linked to the same locus (Hentati
et al, 1994; Gispert et al., 1995). Genetic linkage to
chromosome 2p (SPG4) was demonstrated in 12 families,
seven French and one Dutch (Hazan et al., 1994), three
North American and one Tunisian (Hentati et al., 1994).
In a North American family with ADSP, the locus was
mapped to chromosome 15q (SPG5) (Fink et al., 1995ft).
In this study, the clinical features of ADSP genetically
linked to SPG4 were analysed in 12 families of different
geographic origins to define the characteristics of this
disorder, and their variability among a genetically homo-
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geneous group of patients, compared with SPG3 and SPG5
kindreds.
Methods
Patients
One hundred and seventy-seven individuals from 12 families
with spastic paraplegia were included in this study. The
kindreds are shown in Fig. 1, except the already published
families: 618, 624, 625 (Fontaine et al, 1995) and family A
(Hazan et al, 1993). Two published families, 627 and 645
were re-examined: the status of individuals 627-III-1, 627-
IV-1, 627-1V-3 and 645-IV-8 had changed, and a new patient
645-III-6 was added (Fig. 1). Seven families were French
(618, 624, 625, 627, 645, 4014, A), three Swiss (2992, 5330,
5226), one Polish (1620) and one Portuguese (3266).
The clinical inclusion criteria for the index cases, prior to
the linkage study, were the existence of progressive spastic
paraplegia with pyramidal signs in the lower limbs and a
pattern of segregation of the disease in the family, compatible
with autosomal dominant inheritance. The patients were
classified: definitely affected if they had spasticity, increased
reflexes in the lower limbs and an extensor plantar response;
probably affected if only increased reflexes in the lower
limbs or extensor plantar response were present; possibly
affected if they had brisker reflexes in the lower than in
the upper limbs. Disability was assessed on a three-point
scale: 1 = normal gait or very slight stiffness in the legs;
2 = unable to run, but able to walk without help; 3 = unable
to walk without help or chairbound. A severity score related
to disease duration was obtained by dividing the disability
score by disease duration in years and multiplying by 100.
Age at onset calculations included eight deceased patients at
the time of the study for whom clinical data were available.
Statistical significance was determined with the Yates
corrected x2 test and with the Mann-Whitney U comparison.
Parent-offspring and sibship resemblance was tested by
intraclass and interclass analysis.
Genetic linkage analysis
Informed consent was obtained from each family member
and each control individual. Blood samples from the family
members and from unrelated control individual were drawn,
and genomic DNA was prepared according to standard
procedures (Gusella, 1986). Polymerase chain reaction
amplification and genotyping of the dinucleotide repeats
were performed as described in Hazan et al. (1992). The
dinucleotide repeats used in this study were D2S352, D2S400
and D2S367 (Gyapay et al, 1994). Two newly identified
dinucleotide repeats D2S2347 and D2S2351 were also used
(Dib et al., 1996). Both loci map within the 3 cM interval
flanked by D2S352 and D2S367 (Fig. 2).
Pairwise lod-scores were calculated with the M-LINK
program of the computer package LINKAGE (version 5.1)
(Lathrop et al., 1985). A frequency of 0.0001 was assumed
for ADSP. To perform linkage analysis, liability classes were
determined from the cumulative age at onset curve for
the studied families: 0-19 years, 0.17; 20-24 years, 0.32;
25-30 years, 0.55; 31-51 years, 0.92; >51 years old, 0.99
(Fontaine et al., 1995). Equal allele frequencies were used.
Recombination fractions were assumed to be equal beween
men and women. For linkage analysis, definitely affected
individuals were considered as affected, the status of probably
and possibly affected individuals was considered to be
undetermined. Genetic homogeneity was tested with the
program HOMOG (Ott, 1991).
Results
Clinical examination revealed spastic paraparesis in 95
patients, including 83 with definite, 10 with probable and two
with possible spastic paraplegia as defined above (Table 1).
Linkage analysis
Lod-scores for the tested markers were positive in the 12
families (Table 2). For D2S2351 and D2S2347, total peak-lod-
scores were 19.16 and 21.30, respectively, for a recombination
fraction of 9 = 0.00. HOMOG analysis confirmed the genetic
linkage of the families to chromosome 2, with posterior
probabilities of linked type ranging from 0.75 to 0.99 for
D2S2351. Similar results were obtained for the other three
markers (data not shown).
Genotypes of probable and possible cases
Phenotype-genotype correlations confirmed the clinical
suspicion in nine out of 12 probable or possible cases (Table
3). Three probably affected patients did not carry the disease
haplotype: a 54-year-old woman and a 51-year-old man, both
with hyper-reflexia in the lower limbs and flexor plantar
response, and a 6-year-old girl with clearly increased reflexes
in the lower limbs but no extensor plantar response. No other
neurological abnormalities were noticed in either patient. In
another woman with a diagnosis of probable spastic
paraplegia, leg spasticity began at age 26 years, but at the
time of examination, at age 42 years, she had experienced
relapsing episodes of motor weakness. Cerebrospinal fluid
and MRI studies were suggestive of multiple sclerosis, but
she, as well as the two possibly affected individuals, all carried
the disease haplotype. Among the 82 at-risk individuals with
normal neurological examination only one, aged 57 years,
carried the disease haplotype.
Clinical analysis of 83 patients with definite
spastic paraplegia
Mean age at examination was 45 ±20 years, ranging from 3
to 85 years. Functional impairment was absent or slight in
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Table 1 Twelve families with pure autosomal dominant spastic paraplegia linked to the SPG4 locus on chromosome 2p
Family
618
624
625
627
645
1620
4014
A
2992
3266
5330
5226
Total
No. of patients with
Definite*
10(3)
4 ( 1 )
6(3)
8(4)
7(3)
8(1)
6(3)
7(0)
6(0)
8(4)
9(1)
4(0)
83 (23)
spastic paraplegia
Probable
0
1
0
2
4
0
2
1
0
0
0
0
10
Possible
0
0
0
1
1
0
0
0
0
0
0
0
2
Mean age (years)
at examination (n
32 ±20
50±25
40±21
38±21
48+19
47±17
26±12
43±19
52±16
45±17
49±15
67±19
43 ±20 (3-85)
= 95) at onset (« = 61)
24± 17 (17-51)
37 ±10 (25^5)
25
37 ±12 (25-53)
37 ±21 (5-63)
22 ±22 (2-62)
12±11 (1-22)
21 ±10 (4-30)
31 ±7 (20-40)
43±7 (35-50)
30±14(l-45)
33±16 (10-45)
29±15 (1-63)
*Unaware of symptoms.
27% (n = 22), moderate with inability to run in 41% (n =
34) and severe in 32% (n = 27), who walked with help
or were wheelchair-bound. The overall clinical picture is
presented in Table 4. There was no significant clinical
difference between men (n = 42) and women (n = 41),
except the frequence of sphincter disturbances, more often
mentioned in women (P < 0.05).
Age at onset and anticipation
The age at onset could be determined for 61 patients, 23
were unaware of symptoms but were definitely affected, and
one, aged 77 years, could not remember when his symptoms
first began. The mean age at onset was 29± 15 years, ranging
from 1 to 63 years. In more than half of the patients, 37 out
of 61, the disease started before the age of 35 years. Mean
age at onset was not statistically different among families
(P = 0.15), but decreased in successive generations (Table
5). Mean age at onset was significantly earlier in generation
III than in generation I or II (P < 0.001), but the proportion
of gene carriers, asymptomatic or unaware of their symptoms,
significantly increased in successive generations (P < 0.001),
reaching 100% in generation IV. In 33 parent-offspring pairs,
age at onset was a mean 7 years earlier in offspring (P <
0.005); the mean age at onset in parents was 35±13 years
and in their children of 28± 15 years. The differences ranged
from 58 years earlier to 32 years later than the age at onset
of their parents. There was a positive correlation between
age at onset of parents and anticipation (r = 0.57, P < 0.001).
This suggested an observation bias, since the likelihood of
observing an earlier age at onset in children is greater when
the parent is older (Fig. 3); however, among the 33 parent-
child pairs, 20 showed anticipation and 12 anti-anticipation
and in one, the age at onset was the same in the parent and
the child. This distribution was not significantly different
from the null hypothesis that half of the offspring had an
earlier and half a later onset than the parent (P = 0.22).
Clinical signs according to age at onset and
disease duration
In accordance with Harding's classification (1981), we
divided the patients in two groups, with onset before and
after age 35 years. There was no significant difference in
the frequency of the clinical signs associated with spastic
paraplegia or in the severity of the disease. Disease duration,
as expected, influenced the clinical picture. Spasticity and
muscle weakness were more severe in advanced stages of
the disease. The frequency of urinary urgency and decreased
vibration sense increased with the duration of the disease. In
contrast, hyper-reflexia in the upper limbs did not increase
with evolution. To evaluate differences in the clinical course
according to the age at onset, a severity index was calculated
for each individual. The correlation between the age at onset
and the severity index was significant (r = 0.26, P = 0.035).
The older the onset the more severe the course of the disease,
but this correlation is not individual (Fig. 4).
Phenotype-genotype correlations
Comparison between these 12 SPG4 families and 4 SPG4
kindreds reported in the literature (Hentati et al., 1994)
confirmed the wide variability of age at onset, ranging from
1 to 75 years, but no other clinical information was available
for comparison (Table 6). Three SPG3 kindreds had an earlier
mean age at onset but the range was still large (2-50 years)
(Hazan et al., 1993; Hentati etai, 1994; Gispert et al., 1995).
The course of the disease was reported to be more benign in
one family (Hazan et al, 1993), but 40% of the patients
needed help walking in the other (Gispert et al., 1995). The
single SPG5 family was unusual in that age at onset was
less variable, ranging from 12 to 35 years, and all patients
had pes cavus. As in SPG4 kindreds, vibration sense was often
decreased (percentage was not indicated) (Fink et al., 1995a).
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Fig. 1 Pedigrees of families with autosomal dominant spastic paraplegia linked to SPG4. Definitely affected individuals are represented
by filled symbols, probably affected ones by hatched symbols and possibly affected ones by small black symbols. Asterisks indicate
examined and sampled individuals.
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Fig. 3 Correlation between anticipation and the parent's age at
onset. The positive correlation suggests an observation bias since
the likelihood of observing an earlier age at onset in children is
greater the later the parent's age at onset.
Discussion
Families with ADSP were screened for genetic linkage to
chromosome 2p (SPG4). Approximately 40% of the tested
families showed linkage to SPG4, establishing SPG4 as a
major locus for ADSP. We report 12 ADSP families linked
to chromosome 2p (SPG4) with 83 definitely affected
individuals. This represents the largest series of genetically
homogeneous ADSP which enabled us to analyse, in detail,
the clinical characteristics of the disorder. Haplotype
reconstruction confirmed that the SPG4 gene was located in
the interval flanked by D2S400 and D2S367 (Hazan et al,
1994). Haplotype reconstruction also confirmed the genetic
status of the 12 probably or possibly affected individuals,
nine of whom carried the haplotype segregating with the
disease. This indicates that the disease may be suspected in
at-risk individuals on clinical grounds, before they become
aware of symptoms. For example, only increased and spread
reflexes were present in a 10-year-old girl and a 54-year-old
women, both gene carriers. However, three other individuals
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Fig. 4 Correlation between the severity index, defined as the
disability score divided by disease duration in years and
multiplied by 100, and the age at onset in ADSP patients.
with increased reflexes were not gene carriers. Conversely,
a 57-year-old man with a normal neurological examination
turned out to be a gene carrier. Despite some exceptions, this
study demonstrates the presence and the high specificity of
neurological abnormalities in asymptomatic gene carriers,
that should be taken into account in genetics studies or
counselling.
Adult onset was observed in most patients but intrafamilial
variability, and particularly its range (1-63 years), was
considerable, as already reported in 'pure' ADSP (Harding,
1981; Polo et al., 1993; Diirr et al., 1994). These figures do
not reflect the whole population of patients, however, since
onset could only be assessed in 61 out of 93 gene carriers
(66%). The others, with age at examination ranging from 3
to 74 years, were either unaware of their symptoms or
completely asymptomatic. Over one-third of gene carriers
are therefore unaware of their status.
Is the variability in age at onset due to anticipation?
Although the differences in age at onset between generation
I or II and III, and in parent-offspring pairs, suggest
anticipation, it is only apparent, and results from an
observation bias. There are several reasons for this: (i) no
age at onset can be attributed to one-third of the gene carriers,
especially in the youngest generations, who may become
symptomatic later than their parent; (ii) awareness of the
disease in families can result in diagnosis at an earlier
age; (iii) anticipation is strongly correlated with the age at
examination of the transmitting parent, with a tendency for
regression to the mean; (iv) the distribution of parent-child
pairs in which onset in the child is earlier or later than the
parent is not significantly different from the null hypothesis
which postulates absence of anticipation.
The presence of true anticipation would facilitate
identification of the SPG4 gene, by analogy with the five
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Table 2 Pairwise lod-scores with four chromosome 2p markers in 12 families with autosomal dominant spastic paraplegia
Familj
Locus
618
624
625
627
645
1620
2992
3266
5226
5330
4014
A
Total
Locus
618
624
625
627
645
1620
2992
3266
5226
5330
4014
A
Total
Locus
618
624
625
627
645
1620
2992
3266
5226
5330
4014
A
Total
Locus
618
624
625
627
645
1620
2992
3266
5226
5330
4014
A
Total
i Recombination
0.00
D2S352
2.42
0.74
2.38
1.35
No information
1.21
1.99
2.73
0.64
No information
1.02
0.19
14.67
D2S2351
2.31
No information
1.13
1.93
2.13
1.55
3.44
2.01
1.63
1.72
0.66
0.65
19.16
D2S2347
1.18
0.27
2.38
1.14
0.45
2.17
3.19
2.39
1.78
3.69
0.89
2.22
21.75
D2S367
3.56
1.33
-3.89
1.37
2.03
2.18
2.14
2.21
-3.89
0.85
0.53
2.63
11.05
fraction
0.01
2.38
0.72
2.33
1.36
1.18
1.96
2.68
0.61
1.00
0.19
14.41
2.27
1.10
1.89
2.09
1.52
3.38
1.96
1.60
1.69
0.65
0.64
18.79
1.16
0.26
2.33
1.12
0.44
2.13
3.13
2.35
1.75
3.62
0.87
2.17
21.33
3.50
1.30
-0.22
1.39
1.99
2.14
2.10
2.16
-0.24
0.84
0.52
2.58
18.06
0.05
2.20
0.64
2.15
1.36
1.06
1.82
2.47
0.52
0.92
0.17
13.31
2.09
1.00
1.74
1.93
1.38
3.13
1.78
1.46
1.57
0.59
0.58
17.25
.06
0.23
2.15
1.03
0.39
.95
2.90
2.15
.60
3.37
0.80
.98
19.61
3.25
1.19
0.36
1.38
1.86
1.96
1.94
1.96
0.36
0.78
0.48
2.41
17.93
0.10
1.96
0.54
1.92
1.28
0.91
1.63
2.19
0.43
0.81
0.15
11.82
1.85
0.86
1.55
1.73
1.21
2.81
1.55
1.28
1.43
0.51
0.51
15.29
0.93
0.19
.92
0.92
0.34
1.73
2.60
.90
1.42
3.03
0.71
1.73
17.42
2.92
.04
0.49
1.30
1.68
1.73
1.72
1.71
0.52
0.71
0.43
2.18
16.43
0.20
1.45
0.34
1.41
1.01
0.61
1.21
1.61
0.28
0.60
0.11
8.63
1.34
0.58
1.15
1.28
0.85
2.11
1.08
0.90
1.09
0.36
0.39
11.13
0.65
0.12
1.41
0.67
0.22
1.25
1.96
1.36
1.02
2.31
0.53
1.19
12.69
2.21
0.74
0.45
1.02
1.26
1.26
1.25
1.18
0.51
0.53
0.32
1.67
12.40
0.30
0.88
0.17
0.87
0.64
0.32
0.73
0.97
0.15
0.39
0.06
5.18
0.79
0.29
0.72
0.78
0.51
1.33
0.62
0.50
0.66
0.22
0.28
6.70
0.35
0.06
0.87
0.40
0.12
0.75
1.23
0.78
0.58
1.51
0.35
0.63
7.63
1.42
0.45
0.27
0.65
0.78
0.77
0.74
0.65
0.35
0.34
0.21
1.10
7.73
0.40
0.30
0.05
0.32
0.24
0.09
0.23
0.34
0.05
0.19
0.02
1.83
0.27
0.07
0.28
0.28
0.21
0.47
0.23
0.14
0.23
0.10
0.15
2.43
0.10
0.01
0.32
0.13
0.05
0.30
0.44
0.25
0.17
0.64
0.18
0.13
2.72
0.59
0.20
0.08
0.25
0.28
0.32
0.23
0.21
0.13
0.15
0.10
0.49
3.03
#max
0.00
0.00
0.00
0.02
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.13
0.02
0.00
0.00
0.00
0.00
0.14
0.00
0.00
0.00
0.02
Smax
2.42
0.74
2.38
1.37
1.21
1.99
2.73
0.64
1.02
0.19
14.67
2.31
1.13
1.93
2.13
1.55
3.44
2.01
1.63
1.72
0.66
0.65
19.16
1.18
0.27
2.38
1.14
0.45
2.17
3.19
2.39
1.78
3.69
0.89
2.22
21.75
3.56
1.33
0.50
1.39
2.03
2.18
2.14
2.21
0.55
0.85
0.53
2.63
18.27
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Table 3 Phenotype-genotype correlations in probably and possibly affected individuals with spastic paraplegia
Sex Age at Lower limbs Plantar reflex HaplotypeIndividual Clinical
classification
 t
examination reflexes response
624-IV-3
627-III-1
627-III-2
627-IV-3
645-III-6
645-111-10
645-111-12
645-IV-3
645-IV-lO
4014-II-4
4014-III-4
A-III-16^
Probable
Possible
Probable
Probable
Probable
Probable
Probable
Probable
Possible
Probable
Probable
Probable
F
M
M
F
F
F
F
F
M
M
F
F
21
30
32
6
51
54
49
22
24
35
10
42
+ + *
Extensor
Indifferent
Flexor
Flexor
Indifferent
Flexor
Flexor
Indifferent
Indifferent
Unilateral
Flexor
Extensor
+ = normal, + + = increased reflexes. *Unilateral hyper-reflexia; tspastic paraplegia at the age of 26 years followed at 42 years by
relapsing episodes of motor weakness, then sphincter disturbances; oligoclonal gammaglobulin bounds in CSF and MRI lesions
supporting the diagnosis of multiple sclerosis were seen.
Table 4 Clinical picture in 83 patients with definite spastic
paraplegia linked to SPG4 on chromosome 2p
other neurodegenerative disorders with anticipation in which
the expansion of a translated CAG repeat has been
demonstrated (Sutherland and Richards, 1995). Even in these
disorders, however, anticipation calculated among generations
or in parent-offspring pairs is overestimated due to an
observation bias (Diirr et al., 1996). Therefore, although the
hypothesis of a CAG repeat expansion as the molecular basis
of SPG4 is not supported by our data, it cannot be ruled out.
Allelic heterogeneity at the SPG4 locus can also be excluded
as the source of variability in age at onset, since variance
within and among families is similar.
The SPG4 kindreds studied here do not conform to the
classification of ADSP into two types according to age at
onset, as proposed by Harding (1981). First, both type I and
II patients were found in most SPG4 families making
their classification impossible. Secondly, the frequency of
associated signs, such as decreased vibration sense or urinary
symptoms, did not vary as a function of age at onset. Thirdly,
disease progression, variable and slightly more severe in late
onset patients cannot be used to predict the progression of
the disease.
The comparison of the phenotypes of SPG4 patients with
published SPG3 and SPG5 patients (Hazan et al., 1993;
Hentati et al., 1994; Gispert et al., 1995; Fink et al., 1995a)
has brought certain differences to light. Although the number
of SPG3 and SPG5 patients is too small for reliable genotype-
Table 5 Difference between age at examination and age at onset in different generations of gene
carriers
Number of families
Number of patients
Mean age at examination (years)
Mean age at onset (years)
Number of affected individuals unaware of
symptoms
Functional handicap
Normal or slight
Cannot run
Walk with help or wheelchairbound
Spasticity in the lower limbs
None
Mild
Moderate
Severe
Hyper-reflexia in the upper limbs
Extensor plantar reflexes
Proximal or generalized weakness in the
lower limbs
Impaired vibration sense
Urinary urgency or incontinence
Pes cavus
Dysarthria
Supranuclear ophthalmoplegia
Mental retardation
12
83
45 ±20 (3-85)
29±15 (1-63)
23
27%
41%
32%
23%
21%
31%
25%
22%
86%
53%
56%
34%
12%
4%
2%
2%
Generations Mean age at examination*
(years)
Mean age at onset**
(range) (years)
% unaware of
their status"
II
III
IV
72±11 (« = 10)
56±8 (n = 36)
31 ±6 (n = 38)
10±5 (n = 8)
33±21 (10-63)n = 8
35±13 (2-53) n = 31
19±11 (1-35) n = 22
10
19
42
100
*P < 0.001 for generation II and I compared with generation III; "P < 0.001 between generations
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Table 6 Phenotype-genotype correlations in ADSP families
Number of families
Number of patients
Mean age at onset (years)
Patients with severe functional handicap
Decreased vibration sense
Urinary symptoms
Pes cavus
Locus SPG3 (14q)
Hazan et al.,
1993
1
18
6 (2-50)
6%
0%
ND
ND
Hentati et al..
1994
1
10
<5 (5-14)
ND
ND
ND
ND
Gispert et al.,
1995
1
15
<13
40%
ND
ND
ND
SPG5 (15q)
Fink et al..
1995
1
31
22 ±5 (12-35)
29% (9/31)
Often mildlv
10%
Always present
SPG4 (2p)
Hentati et al..
1994
4
35
>35 (2-75)
ND
ND
ND
ND
Present study
12
83
29±15 (2-63)
11% (9/83)
56%
34%
12%
phenotype correlations, the mean age at onset was clearly
earlier in the SPG3 than in the SPG4 or SPG5 groups, adult
onset was still found in one out of the 18 SPG3 patients
(Hazan et al, 1993). True anticipation was not apparent in
SPG4 and SPG5 families. However, in one SPG3 kindred
the severity increased from one generation to the next (Hazan
et al., 1993). Decreased vibration sense and urinary symptoms
were common in SPG4 and SPG5, but absent in SPG3
patients. On the contrary, pes cavus found in all SPG5
patients is rarely observed in those with SPG4. In spite of
these differences, the variability in age at onset and clinical
presentation of SPG4 patients prevent the application of
phenotype-genotype correlation to single affected
individuals.
In conclusion, the major locus for ADSP, SPG4 on
chromosome 2, is characterized by a marked intrafamilial
variability of age at onset and severity. This variability does
not result from anticipation or allelic heterogeneity but could
be due to other genetic or environmental factors. Careful
clinical evaluation of at risk family members can identify
most presymptomatic carriers, but accurate diagnosis can
only be obtained by haplotype reconstruction. The high
frequency of gene carriers unaware of their status is
particularly important for genetic counselling.
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